Desipramine treatment has minimal effects on the brain accumulation of glucocorticoids in P-gp-deficient and wild-type mice

Psychoneuroendocrinology

Volumn 36, Issue 9, 2011, Pages 1351-1360

  Mason, Brittany L ^a   Thomas, Sarah A ^a   Lightman, Stafford L ^b   Pariante, Carmine M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Antidepressants; Blood brain barrier; Desipramine; Glucocorticoids; Hypothalamic pituitary adrenal (HPA) axis

Indexed keywords

CORTICOSTERONE; DESIPRAMINE; DEXAMETHASONE; GLUCOCORTICOID; GLYCOPROTEIN P; HYDROCORTISONE; TRITIUM;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD BRAIN BARRIER; BRAIN ACCUMULATION; BRAIN PERFUSION; CENTRAL NERVOUS SYSTEM; CEREBELLUM; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG MECHANISM; FRONTAL CORTEX; HYPOTHALAMUS; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BLOOD-BRAIN BARRIER; BRAIN; CHOROID PLEXUS; CORTICOSTERONE; DESIPRAMINE; DEXAMETHASONE; GLUCOCORTICOIDS; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; PITUITARY GLAND;

EID: 80052731723     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2011.03.008     Document Type: Article

References (42)

1. Anacker C., Zunszain P.A., Carvalho L.A., Pariante C.M. The glucocorticoid receptor: pivot of depression and of antidepressant treatment?. Psychoneuroendocrinology 2011, 36:415-425.
2. Anacker, C., Zunszain, P.A., Cattaneo, A., Carvalho, L.A., Garabedian, M.J., Thuret, S., Price, J., Pariante, C.M., 2011b. Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol. Psychiatr., in press.
3. Borst P., Schinkel A.H. What have we learnt thus far from mice with disrupted P-glycoprotein genes?. Eur. J. Cancer 1996, 32A:985-990.
4. Cameron A., Henley D., Carrell R., Zhou A., Clarke A., Lightman S. Temperature-responsive release of cortisol from its binding globulin: a protein thermocouple. J. Clin. Endocr. Metab. 2010, 95:4689-4695.
5. Carvalho L.A., Pariante C.M. In vitro modulation of the glucocorticoid receptor by antidepressants. Stress 2008, 11:411-424.
6. Choudhuri S., Cherrington N.J., Li N., Klaassen C.D. Constitutive expression of various xenobiotic and endobiotic transporter mRNSs in the choroid plexus of rats. Drug Metab. Dispos. 2003, 31:1337-1345.
7. Clarke G., O'Mahoney S.M., Cryan J.F., Dinan T.G. Verapamil in treatment resistant depression: a role for the P-glycoprotein transporter?. Human Psychopharm. 2009, 24:217-223.
8. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at the blood-brain barrier sites. Proc. Natl. Acad. Sci. 1989, 86:695-698.
9. de Klerk O.L., Willemsen A.T., Roosink M., Bartels A.L., Harry Hendrikse N., Bosker F.J., den Boer J.A. Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier. Int. J. Neuropsychopharm. 2009, 12:895-904.
10. de Klerk O.L., Bosker F.J., Willemsen A.T., Van Waarde A., Visser A.K., de Jager T., Dagyte G., den Boer J.A., Dierckx R.A., Meerlo P. Chronic stress and antidepressant treatment have opposite effects on P-glycoprotein at the blood-brain barrier: an experimental PET study in rats. J. Psychopharmacol. 2010, 24:1237-1242.
11. Gazzin S., Strazielle N., Schmitt C., Fevre-Montange M., Ostrow J.D., Tirbelli C., Ghersi-Egea J.-F. Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between blood-brain interfaces. J. Comp. Neurol. 2008, 510:497-507.
12. Holsboer F., Liebl R., Hofschuster E. Repeated dexamethasone suppression test during depressive illness. J. Affect. Disord. 1982, 4:93-101.
13. Johanson C.E., Duncan J.A., Klinge P.M., Brinker T., Stopa E.G., Silverberg G.D. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res. 2008, 5:10-41.
14. Johnson A.K., Gross P.M. Sensory circumventricular organs and brain homeostatic pathways. FASEB J. 1993, 7:678-686.
15. Juruena M.F., Cleare A.J., Papadopoulos A.S., Poon L., Lightman S., Pariante C.M. The prednisolone suppression test in depression: dose-response and changes with antidepressant treatment. Psychoneuroendocrinology 2010, 35:1486-1491.
16. Karssen A.M., Meijer O.C., van der Sandt I.C.J., Lucassen P.J., de Lange E.C.M., de Boer A.G., de Kloet E.R. Multidrug resistance p-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 2001, 142:2686-2694.
17. Kassem N.A., Deane R., Segal M.B., Chen R., Preston J.E. Thyroxine (T4) transfer from CSF to choroid plexus and ventricular brain regions in rabbit: contributory role of P-glycoprotein and organic anion transporting polypeptides. Brain Res. 2007, 1181:44-50.
18. Kotelevtsev Y., Holmes M.C., Burchell A., Houston P.M., Schmoll D., Jamieson P., Best R., Brown R., Edwards C.R.W., Seckl J.R., Mullins J.J. 11ß-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. 1997, 94:14924-14929.
19. Lightman S.L. The neuroendocrinology of stress: a never ending story. J. Neuroendocrinol. 2008, 20:880-884.
20. Matsson P., Pedersen J.M., Norinder U., Bergström C.A., Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm. Res. 2009, 26:1816-1831.
21. Mason B.L., Pariante C.M. The effects of antidepressants on the hypothalamic-pituitary-adrenal axis. Drug News Perspect. 2006, 19:603-608.
22. Mason B.L., Pariante C.M., Thomas S.A. A revised role for P-glycoprotein in the brain distribution of dexamethasone, cortisol, and corticosterone in wild-type and ABCB1A/B-deficient mice. Endocrinology 2008, 149:5244-5253.
23. Mason B.L., Pariante C.M., Jamel S., Thomas S.A. Central nervous system (CNS) delivery of glucocorticoids is fine-tuned by saturable transporters at the blood-CNS barriers. Endocrinology 2010, 151:5294-5305.
24. Meijer O.C., de Lange E.C.M., Breimer D.D., de Boer A.G., Workel J.O., de Kloet E.R. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1a p-glycoprotein knockout mice. Endocrinology 1998, 139:1789-1793.
25. Pariante C.M., Pearce B.D., Pisell T.L., Owens M.J., Miller A.H. Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol. Pharmacol. 1997, 52:571-581.
26. Pariante C.M., Makoff A., Lovestone S., Feroli S., Heyden A., Miller A.H., et al. Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br. J. Pharmacol. 2001, 134:1335-1343.
27. Pariante C.M., Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatr. 2001, 49:391-404.
28. Pariante C.M., Hye A., Williamson R., Makoff A., Lovestone S., Kerwin R.W. The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology 2003, 28:1553-1561.
29. Pariante C.M., Kim R.B., Makoff A., Kerwin R.W. Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br. J. Pharmacol. 2003, 139:1111-1118.
30. Pariante C.M., Thomas S.A., Lovestone S., Makoff A., Kerwin R.W. Do antidepressants regulate how cortisol affects the brain?. Psychoneuroendocrinology 2004, 29:423-447.
31. Pariante C.M. Risk factors for development of depression and psychosis: glucocorticoid receptors and pituitary implications for treatment with antidepressants and glucocorticoids. Ann. N. Y. Acad. Sci. 2009, 1179:144-152.
32. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008, 31:464-468.
33. Rao V.V., Dahlheimer J.L., Bardgett M.E., Snyder A.Z., Finch R.A., Sartorelli A.C., Piwnica-Worms D. Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc. Natl. Acad. Sci. 1999, 96:3900-3905.
34. Russell G.M., Henley D.E., Leendertz J., Douthwaite J.A., Wood S.A., Stevens A., Woltersdorff W.W., Peeters B.W., Ruigt G.S., White A., Veldhuis J.D., Lightman S.L. Rapid glucocorticoid inhibition of hypothalamic-pituitary-adrenal ultradian activity in healthy males. J. Neurosci. 2010, 30:6106-6115.
35. Sanderson L., Khan A., Thomas S. Distribution of suramin, an antitrypanasomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice. Antimicrob. Agents Chemother. 2007, 51:3136-3146.
36. Schinkel A.H., Mayer U., Wagenaar E., Mol C.A.A.M., van Deemter L., Smit J.J.M., van der Valk M.A., Woordouw A.C., Spits H., van Tellingen O., Zulmans J.M.J.M., Fibe W.E., Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. 1997, 94:4028-4033.
37. Schinkel A.H. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 1999, 36:179-194.
38. Uhr M., Holsboer F., Muller M.B. Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b p-glycoproteins. J. Neuroendcrinol. 2002, 14:753-759.
39. Vreeburg S.A., Hoogendijk W.J.G., van Pelt J., DeRijk R.H., Verhagen J.C.M., van Dyck R., Smit J.H., Zitman F.G., Penninx B.W.J.H. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch. Gen. Psychiatr. 2009, 66:617-626.
40. Weber C.-C., Eckert G.P., Müller W.E. Effects of antidepressants on the brain/plasma distribution of corticosterone. Neuropsychopharmacology 2006, 31:2443-2448.
41. Weber C.-C., Kressmann S., Ott M., Fricker G., Müller W.E. Inhibition of P-glycoprotein function by several antidepressants may not contribute to clinical efficacy. Pharmacopsychiatry 2005, 38:293-300.
42. Yau J.L.W., Noble J., Thomas S., Kerwin R., Morgan P.E., Lightman S., Seckl J.R., Pariante C.M. The antidepressant desipramine requires the ABCB1 (mdr1)-type p-glycoprotein to upregulate the glucocorticoid receptor in mice. Neuropsychopharmacology 2007, 32:2520-2529.